Human Biliary Amount Prediction Using Simple, Bile Flow-Rate Corrected and Uridine Diphosphate Glucuronosyltransferase Activity Corrected Allometric Methods

References

• Bhamidapati RK , MullangiR , SrinivasNR . Interspecies scaling of urinary excretory amounts of nine drugs belonging to different therapeutic areas with diverse chemical structures – accurate prediction of the human urinary excretory amounts . Xenobiotica47 ( 2 ), 112 – 118 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Srinivas NR . Interspecies scaling of excretory amounts using allometry - retrospective analysis with rifapentine, aztreonam, carumonam, pefloxacin, miloxacin, trovafloxacin, doripenem, imipenem, cefozopran, ceftazidime, linezolid for urinary excretion and rifapentine, cabotegravir, and dolutegravir for fecal excretion . Xenobiotica46 ( 9 ), 784 – 792 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Mahmood I , SahajwallaC . Interspecies scaling of biliary excreted drugs . J. Pharm. Sci.91 ( 8 ), 1908 – 1914 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Mahmood I . Interspecies scaling of biliary excreted drugs: a comparison of several methods . J. Pharm. Sci.94 ( 4 ), 883 – 892 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Ward KW , AzzaranoLM , BondinellWEet al. Preclinical pharmacokinetics and interspecies scaling of a novel vitronectin receptor antagonist . Drug Metab. Disp.27 ( 11 ), 1232 – 1241 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Benjamin B , SahuM , BhatnagarU , AbhyankarD , SrinivasNR . The observed correlation between in vivo clinical pharmacokinetic parameters and in vitro potency of VEGFR-2 inhibitors. Can this be used as a prospective guide for the development of novel compounds?Arzneimittelforschung.62 ( 4 ), 194 – 201 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Srinivas NR . Limited sampling strategy for the prediction of area under the curve (AUC) of statins: reliability of a single time point for AUC prediction for pravastatin and simvastatin . Drug Res. (Stuttg).66 ( 2 ), 82 – 93 ( 2016 ).
   PubMedGoogle Scholar
• Srinivas NR . Therapeutic drug monitoring of cyclosporine and area under the curve prediction using a single time point strategy: appraisal using peak concentration data . Biopharm. Drug Dispos.36 ( 9 ), 575 – 586 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Srinivas NR . Differences in the prediction of area under the curve for a protease inhibitor using trough versus peak concentration: assessment using published pharmacokinetic data for indinavir . Am. J. Ther. ( 2015 ) ( Epub ahead of print ).
   Web of Science ®Google Scholar
• Srinivas NR . Prediction of area under the curve for a P-glycoprotein, a CYP3A4 and a CYP2C9 substrate using a single time point strategy: assessment using fexofenadine, itraconazole and losartan and metabolites . Drug Dev. Ind. Pharm.42 ( 6 ), 945 – 957 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Grime K , PaineSW . Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement . Drug Metab. Dispos.41 ( 2 ), 372 – 378 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Davies B , MorrisT . Physiological parameters in laboratory animals and humans . Pharm. Res.10 ( 7 ), 1093 – 1096 ( 1993 ).
   PubMed Web of Science ®Google Scholar
• Black AE , HayesRN , RothBD , WooP , WoolfTF . Metabolism and excretion of atorvastatin in rats and dogs . Drug Metab. Dispos.27 ( 8 ), 916 – 923 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Zhang D , WangL , RaghavanNet al. Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling . Drug Metab. Dispos.35 ( 1 ), 150 – 167 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• EMA/604444/2011, Trajenta® (Linagliptin): assessment report, (CHMP) . www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002110/WC500115748.pdf .
   Google Scholar
• Gong J , GanJ , CaceresCJet al. Metabolism and disposition of [14C]brivanib alaninate after oral administration to rats, monkeys, and humans . Drug Metab. Dispos.39 ( 5 ), 891 – 903 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Kassahun K , BlackWC , NicollGDet al. Pharmacokinetics and metabolism in rats, dogs, and monkeys of the cathepsin k inhibitor odanacatib: demethylation of a methylsulfonyl moiety as a major metabolic pathway . Drug Metab. Dispos.39 ( 6 ), 1079 – 1087 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Kassahun K , McIntoshI , KoeplingerKet al. Disposition and metabolism of the cathepsin k inhibitor odanacatib in humans . Drug Metab. Dispos.42 ( 5 ), 818 – 827 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Maurer G , SchreierE , DelabordeS , NuferR , ShuklaAP . Fate and disposition of bromocriptine in animals and man. II: absorption, elimination and metabolism . Eur. J. Drug Metab. Pharmacokin.8 ( 1 ), 51 – 62 ( 1983 ).
   PubMed Web of Science ®Google Scholar
• Roffey SJ , ObachRS , GedgeJI , SmithDA . What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs . Drug Metab. Rev.39 ( 1 ), 17 – 43 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Blech S , SchwellingerEL , Grafe ModyEU , WithopfB , WagnerK . The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans . Drug Metab. Dispos.38 ( 4 ), 667 – 678 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Schaefer WH , PolitowskiJ , HwangBet al. Metabolism of carvedilol in dogs, rats, and mice . Drug Metab. Dispos.26 ( 10 ), 958 – 969 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Lau YY , OkochiH , HuangY , BenetLZ . Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism . Drug Metab. Dispos.34 ( 7 ), 1175 – 1181 ( 2006 ).
   PubMed Web of Science ®Google Scholar